Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

Home
/
update
/
details

ANGLE plc Publishes Study Demonstrating Parsortix® System’s Role in Prostate Cancer Biomarker Detection and Therapy Development

NextEdge Admin

18 Oct 2024

2 min 19 sec

ANGLE , a global leader in liquid biopsy solutions, announced the publication of research conducted by the Comprehensive Cancer Center at the Medical University of Vienna, focusing on prostate cancer biomarkers in circulating tumor cells (CTCs).

Using ANGLE’s Parsortix® system, CTCs were isolated and harvested from 38 patients with localized and metastatic prostate cancer. The captured CTCs underwent advanced molecular analysis, allowing simultaneous examination of multiple gene biomarkers.

The study demonstrated the Parsortix system’s high efficiency in detecting CTC biomarkers, with 67% of localized prostate cancer patients testing positive at baseline and 77% showing biomarker positivity after treatment. The analysis revealed a strong correlation between specific CTC biomarkers and clinical characteristics, such as tumor grade and stage, suggesting the potential of multi-marker CTC analysis in refining patient risk stratification.

These findings support ANGLE’s pharmaceutical strategy by demonstrating how Parsortix-enriched, CTC-based approaches can enhance patient selection and stratification in clinical trials. This method could inform the development of more precise therapies, improving patient outcomes and potentially leading to new classes of targeted drugs.

Karen Miller, ANGLE’s Chief Scientific Officer, emphasized the significance of the study:
“This research highlights how our CTC multi-marker approach can accelerate the development of targeted therapies, enhance trial designs, and optimize patient outcomes. It also suggests the potential need for Parsortix-based companion diagnostics to support regulatory approval.”

The study was published in the peer-reviewed journal Clinical and Experimental Metastasis.